Venus Medtech (Hangzhou) (HKSE:02500) EV-to-EBIT : -3.44 (As of May. 25, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Venus Medtech (Hangzhou) EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Venus Medtech (Hangzhou)'s Enterprise Value is HK$2,527.4 Mil. Venus Medtech (Hangzhou)'s EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-735.7 Mil. Therefore, Venus Medtech (Hangzhou)'s EV-to-EBIT for today is -3.44.

The historical rank and industry rank for Venus Medtech (Hangzhou)'s EV-to-EBIT or its related term are showing as below:

HKSE:02500' s EV-to-EBIT Range Over the Past 10 Years
Min: -155.8 Med: -12.44 Max: -0.59
Current: -3.44

During the past 7 years, the highest EV-to-EBIT of Venus Medtech (Hangzhou) was -0.59. The lowest was -155.80. And the median was -12.44.

HKSE:02500's EV-to-EBIT is ranked worse than
100% of 458 companies
in the Medical Devices & Instruments industry
Industry Median: 20.17 vs HKSE:02500: -3.44

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Venus Medtech (Hangzhou)'s Enterprise Value for the quarter that ended in Dec. 2023 was HK$2,525.8 Mil. Venus Medtech (Hangzhou)'s EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-735.7 Mil. Venus Medtech (Hangzhou)'s Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -29.13%.

Venus Medtech (Hangzhou) EV-to-EBIT Historical Data

The historical data trend for Venus Medtech (Hangzhou)'s EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Venus Medtech (Hangzhou) EV-to-EBIT Chart

Venus Medtech (Hangzhou) Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-30.53

-139.07

-20.93

-4.21

-3.43

Venus Medtech (Hangzhou) Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial							-20.93	-	-4.21	-	-3.43

Competitive Comparison of Venus Medtech (Hangzhou)'s EV-to-EBIT

For the Medical Devices subindustry, Venus Medtech (Hangzhou)'s EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Venus Medtech (Hangzhou)'s EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Venus Medtech (Hangzhou)'s EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Venus Medtech (Hangzhou)'s EV-to-EBIT falls into.

Venus Medtech (Hangzhou) EV-to-EBIT Calculation

Venus Medtech (Hangzhou)'s EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	2527.429	/	-735.702
	=	-3.44

Venus Medtech (Hangzhou)'s current Enterprise Value is HK$2,527.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Venus Medtech (Hangzhou)'s EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-735.7 Mil.

Venus Medtech (Hangzhou) (HKSE:02500) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Venus Medtech (Hangzhou)'s Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-735.702	/	2525.78582
	=	-29.13 %

Venus Medtech (Hangzhou)'s Enterprise Value for the quarter that ended in Dec. 2023 was HK$2,525.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Venus Medtech (Hangzhou)'s EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-735.7 Mil.

Venus Medtech (Hangzhou) EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Venus Medtech (Hangzhou)'s EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Venus Medtech (Hangzhou) (HKSE:02500) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Venus Medtech (Hangzhou) Inc (HKSE:02500) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

VMTHF:USA

Address

No. 88, Jiangling Road, Room 311, 3rd Floor, Block 2, Binjiang District, Hangzhou, CHN, 310051

Website

https://www.venusmedtech.com

Venus Medtech (Hangzhou) Inc is engaged in the development and commercialization of transcatheter solutions for structural heart diseases. It has two TAVR products on the market, namely VenusA-Valve, and VenusA-Plus. VenusA-Valve is its first-generation TAVR device, which is used to treat severe Aortic Stenosis (AS) using a transcatheter approach. VenusA-Plus is an upgraded product of VenusA-Valve. Geographically all of the revenue is derived from Mainland China.

Executives

Zeng Min Frank	2201 Interest of corporation controlled by you
Zi Zhenjun	2201 Interest of corporation controlled by you
Ming Zhi Investments (bvi) Limited	2101 Beneficial owner
Ming Zhi Investments Limited	2201 Interest of corporation controlled by you
Qiming Venture Partners Iii, L.p.	2201 Interest of corporation controlled by you
Qiming Corporate Gp Iii, Ltd.	2201 Interest of corporation controlled by you
Qiming Gp Iii, L.p.	2201 Interest of corporation controlled by you
Dcp Capital Partners, L.p.	2201 Interest of corporation controlled by you
Dcp General Partner, Ltd	2201 Interest of corporation controlled by you
Dcp, Ltd.	2201 Interest of corporation controlled by you
Liu Haifeng David	2201 Interest of corporation controlled by you
Muheng Capital Partners (hong Kong) Limited	2101 Beneficial owner
Red Giant Limited	2201 Interest of corporation controlled by you
Wolhardt Julian Juul	2201 Interest of corporation controlled by you
Horizon Binjiang Llc	2101 Beneficial owner

Venus Medtech (Hangzhou) (HKSE:02500) Headlines

No Headlines